دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
O'Reilly, Eileen M. MD 1,2,3,,
doi : 10.1200/JCO.23.00898
Volume 41(21) pgs. 3661-3767 July 20, 2023
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
Saltz, Leonard B.; Clarke, Stephen; Di[Combining Acute Accent]az-Rubio, Eduardo; Scheithauer, Werner; Figer, Arie; Wong, Ralph; Koski, Sheryl; Lichinitser, Mikhail; Yang, Tsai-Shen; Rivera, Fernando; Couture, Felix; Sirze[Combining Acute Accent]n, Florin; Cassidy, Jim
doi : 10.1200/JCO.22.02760
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200.
Giantonio, Bruce J.; Catalano, Paul J.; Meropol, Neal J.; O'Dwyer, Peter J.; Mitchell, Edith P.; Alberts, Steven R.; Schwartz, Michael A.; Benson, Al B. III
doi : 10.1200/JCO.22.02761
Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia.
Kipps, Thomas J. MD, PhD 1,
doi : 10.1200/JCO.23.00619
Encorafenib and Binimetinib: A New Treatment Option for BRAFV600E-Mutant Non-Small-Cell Lung Cancer.
Stinchcombe, Thomas E. MD 1,,
doi : 10.1200/JCO.23.00983
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir, Talha MBBS 1,,; Moreno, Carol MD 2,; Owen, Carolyn MD 3,; Follows, George PhD 4,; Benjamini, Ohad MD 5,; Janssens, Ann MD, PhD 6,; Levin, Mark-David MD 7,; Osterborg, Anders MD, PhD 8; Robak, Tadeusz MD, PhD 9,; Simkovic, Martin MD, PhD 10,; Stevens, Don MD 11; Voloshin, Sergey MD, PhD 12,; Vorobyev, Vladimir PhD 13,; Yagci, Munci MD 14,; Ysebaert, Loic MD, PhD 15,; Qi, Keqin PhD 16,; Qi, Qianya PhD 17,; Parisi, Lori MPH 17,; Srinivasan, Srimathi PhD 18,; Schuier, Natasha MD 19,; Baeten, Kurt PhD 20,; Howes, Angela PhD 21,; Caces, Donne Bennett MD, PhD 17,; Niemann, Carsten U. MD, PhD 22,; Kater, Arnon P. MD, PhD 23,
doi : 10.1200/JCO.22.02283
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
Riely, Gregory J. MD, PhD 1,,; Smit, Egbert F. MD, PhD 2,; Ahn, Myung-Ju MD, PhD 3,; Felip, Enriqueta MD, PhD 4,; Ramalingam, Suresh S. MD 5,; Tsao, Anne MD 6,; Johnson, Melissa MD 7,; Gelsomino, Francesco MD 8,; Esper, Raymond MD, PhD 9,; Nadal, Ernest MD, PhD 10,; Offin, Michael MD 1,; Provencio, Mariano MD, PhD 11,; Clarke, Jeffrey MD 12,; Hussain, Maen MD 9,; Otterson, Gregory A. MD 13,; Dagogo-Jack, Ibiayi MD 14,; Goldman, Jonathan W. MD 15,; Morgensztern, Daniel MD 16,; Alcasid, Ann BA 17,; Usari, Tiziana BSc 18,; Wissel, Paul MD 19,; Wilner, Keith PhD 20,; Pathan, Nuzhat PhD 20,; Tonkovyd, Svitlana MD 21,; Johnson, Bruce E. MD 22,
doi : 10.1200/JCO.23.00774
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif, Talal MD 1; Nassar, Amin H. MD 2; Adib, Elio MD 1,3,; Fitzgerald, Bailey G. MD 4; Huang, Jiaming MS 1; Mouhieddine, Tarek H. MD 4,; Rubinstein, Paul G. MD 5; Nonato, Taylor BSc 6; McKay, Rana R. MD 6,; Li, Mingjia MD 7; Mittra, Arjun MD 7,; Owen, Dwight H. MD, MSc 7,; Baiocchi, Robert A. MD, PhD 8,; Lorentsen, Michael MD 9; Dittus, Christopher DO, MPH 9,; Dizman, Nazli MD 2,; Falohun, Adewunmi DO 10; Abdel-Wahab, Noha MD, PhD 10,11,; Diab, Adi MD 10,; Bankapur, Anand MD 12; Reed, Alexandra BA 12; Kim, Chul MD, MPH 13,; Arora, Aakriti MD 14; Shah, Neil J. MBBS 15,; El-Am, Edward MD 16; Kozaily, Elie MD 16; Abdallah, Wassim MD 17; Al-Hader, Ahmad MD 16; Abu Ghazal, Batool MD 18; Saeed, Anwaar MD 18,19,; Drolen, Claire MD 20; Lechner, Melissa G. MD, PhD 20,; Drakaki, Alexandra MD, PhD 20,; Baena, Javier MD 21,; Nebhan, Caroline A. MD 22; Haykal, Tarek MD 23; Morse, Michael A. MD 23,; Cortellini, Alessio MD, PhD 24,25,; Pinato, David J. MD, PhD 24,26,; Dalla Pria, Alessia MD 24,27; Hall, Evan MD 28,; Bakalov, Veli MD 29; Bahary, Nathan MD, PhD 29,; Rajkumar, Aarthi MD 30; Mangla, Ankit MD 30,; Shah, Vishal PharmD, MBA 31; Singh, Parminder MD 31,; Aboubakar Nana, Frank MD 32; Lopetegui-Lia, Nerea MD 33; Dima, Danai MD 33; Dobbs, Ryan W. MD 5,; Funchain, Pauline MD 33,; Saleem, Rabia MD 34; Woodford, Rachel MD 35; Long, Georgina V. MD 36,; Menzies, Alexander M. MD 35,; Genova, Carlo MD, PhD 37,38,; Barletta, Giulia MD 39; Puri, Sonam MD 40,; Florou, Vaia MD 40,; Idossa, Dame MD 41; Saponara, Maristella MD 42,; Queirolo, Paola MD 42,; Lamberti, Giuseppe MD 43; Addeo, Alfredo MD 44,; Bersanelli, Melissa MD, PhD 45,; Freeman, Dory BSc 1; Xie, Wanling MS 1,; Reid, Erin G. MD 6,; Chiao, Elizabeth Y. MD, MPH 10; Sharon, Elad MD, MPH 46; Johnson, Douglas B. MD 22,; Ramaswami, Ramya MD 47,; Bower, Mark MD 24,27,; Emu, Brinda MD 2,; Marron, Thomas U. MD, PhD 4,; Choueiri, Toni K. MD 1,; Baden, Lindsey R. MD 3; Lurain, Kathryn MD, MPH 47,; Sonpavde, Guru P. MD 48,; Naqash, Abdul Rafeh MD 34,
doi : 10.1200/JCO.22.02459
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Basch, Ethan MD, MSc, FASCO 1,,; Dueck, Amylou C. PhD 2; Mitchell, Sandra A. PhD 3; Mamon, Harvey MD, PhD 4,; Weiser, Martin MD 5,; Saltz, Leonard MD 6,; Gollub, Marc MD 7,; Rogak, Lauren MA 6; Ginos, Brenda MS 2; Mazza, Gina L. PhD 2; Colgrove, Brian BS 8; Chang, George MD, MS 9,; Minasian, Lori MD 3; Denicoff, Andrea MS, RN 3; Thanarajasingam, Gita MD 10,; Musher, Benjamin MD 11,; George, Thomas MD 12,; Venook, Alan MD 13,; Farma, Jeffrey MD 14,; O'Reilly, Eileen MD 6,; Meyerhardt, Jeffrey A. MD 15,; Shi, Qian PhD 8,; Schrag, Deborah MD, MPH 6,
doi : 10.1200/JCO.23.00903
Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study.
Reulen, Raoul C. PhD 1,; Winter, David L. HNC 1; Diallo, Ibrahim PhD 2; Veres, Cristina MSc 2; Llanas, Damien PhD 2; Allodji, Rodrigue S. PhD 2; Bagnasco, Francesca PhD 3; Bardi, Edit MD 4,5; Feijen, Elizabeth A.M. PhD 6; Alessi, Daniela PhD 7; Fidler-Benaoudia, Miranda M. PhD 8,9; Hogsholt, Stine MD, PhD 10,11,; Teepen, Jop C. PhD 6; Linge, Helena MD 12,; Haddy, Nadia PhD 2; Byrne, Julianne PhD 13; Debiche, Ghazi PhD 2; Grabow, Desiree PhD 14; Gudmundsdottir, Thorgerdur MD 10,15; Fauchery, Romain PhD 2; Zrafi, Wael MD 2; Michel, Gisela PhD 16; Ofstaas, Hilde PhD 17; Kaatsch, Peter PhD 14; Vu-Bezin, Giao PhD 2; Jenkinson, Helen MD, PhD 18; Kaiser, Melanie PhD 14; Skinner, Roderick MD, PhD 19,; Cole, Trevor PhD 20; Waespe, Nicolas PhD 21,22,23,; Sommer, Grit PhD 22,; Nordenfelt, Susanne MSc 12; Jankovic, Momcilo PhD 24; Lahteenmaki Taalas, Tuomas MD 25,; Maule, Milena M. MD 7; van der Pal, Helena J.H. MD 6; Ronckers, Cecile M. PhD 6,14; van Leeuwen, Flora E. PhD 26; Kok, Judith L. PhD 6; Terenziani, Monica MD 27; Winther Gunnes, Maria PhD 17,28,; Wiebe, Thomas MD 12; Sacerdote, Carlotta PhD 7; Jakab, Zsuzsanna MD 29; Haupt, Riccardo MD 30; Lahteenmaki, Paivi M. MD 25; Zadravec Zaletel, Lorna MD 31; Kuehni, Claudia E. PhD 22,23,; Falck Winther, Jeanette MD, PhD 10,32; Kremer, Leontien C.M. MD, PhD 6,33; Hjorth, Lars MD 12,; de Vathaire, Florent PhD 2; Hawkins, Michael M. DPhil 1
doi : 10.1200/JCO.22.02045
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro, Antonio MD, PhD 1,; Janne, Pasi A. MD, PhD 2,; Peters, Solange MD, PhD 3,
doi : 10.1200/JCO.23.00013
Could Adjuvant Radiotherapy Be Avoided for Postmenopausal Patients With Node-Positive Estrogen Receptor-Positive Breast Cancer and Favorable Recurrence Score and SET2,3 Scores?.
Wang, Yanhong MM; Cai, Qunrong BMed
doi : 10.1200/JCO.23.00210
Nontumor Cells Possibly Cause Bias to the Evaluation of Gene Expression Score.
Sui, Qihai PhD; Hu, Zhengyang PhD; Chen, Zhencong PhD; Zhan, Cheng PhD
doi : 10.1200/JCO.23.00303
Reply to Y. Wang et al and Q. Sui et al.
Speers, Corey W. MD, PhD; Barlow, William E. PhD; Symmans, W. Fraser MD
doi : 10.1200/JCO.23.00722
Reply to Y. Wang et al and Q. Sui et al.
LeVasseur, Nathalie MD, FRCPC; Gelmon, Karen A. MD
doi : 10.1200/JCO.23.00663
Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial.
doi : 10.1200/JCO.23.00901
